Founded in 2010 and based in Barcelona, STAT-Dx develops the DiagCORE in vitro diagnostic system, a cartridge-based single-test platform that consolidates molecular and immunoassay techniques. DiagCORE is designed to identify a wide range of infectious pathogens (meningitis, respiratory, gastro-intestinal) and deliver results in roughly one hour to support faster clinical decisions in ICUs and emergency rooms. The company aims to replace complex diagnostic protocols with a near-to-care solution that tests simultaneously for multiple pathogens associated with syndrome panels. STAT-Dx planned CE-marking for a respiratory panel application by the end of 2017 and is pursuing commercialisation and clinical validation. The business is backed by a strong shareholder base of leading international healthcare investors and has sought institutional financing to bridge early market introduction to wider commercial roll-out. The EIB loan described in the articles is intended to accelerate development, commercialisation and market introduction of the DiagCORE platform. STAT-Diagnostica develops near-patient testing solutions and is the maker of the DiagCORE integrated molecular and immunoassay diagnostics system. DiagCORE performs all on-board sample preparation for a wide range of sample types and offers up to 48-multiplex capability via real-time PCR, with time-to-results of roughly 30–80 minutes depending on the assay. The system is designed for true walk-away diagnostics and aims to deliver lab-like performance with high usability. STAT-Diagnostica plans to target decentralized testing environments including critical care and emergency units, clinics, and physician offices, and the system has CLIA-waivable features for broader use. The company intends to use the financing to prepare for a 2017 European launch of DiagCORE. STAT-Diagnostica was founded in 2010 in Barcelona and is led by CEO and co-founder Jordi Carrera. STAT-Diagnostica builds a versatile in vitro Near Patient Testing platform that consolidates molecular and immunoassay techniques in a single, easy-to-use device. The system offers multi-analyte and multi-sample capabilities and delivers results in less than 30 minutes. Initial clinical applications target infectious disease detection, antibiotic resistance determination, and biomarkers in critically ill patients. The company plans to use the Series B proceeds to complete development of its diagnostic system and to finish clinical validation of its first products. STAT-Diagnostica was founded in 2010 and is based in the Barcelona Science Park. Management has stated the financing will support preparation for a European market launch in 2015. STAT Diagnostica develops point-of-care in-vitro diagnostic solutions for clinical applications. Its platform is designed to perform both molecular diagnostics and immunoassays. The company intends its main applications to address infectious diseases, antibiotic resistance detection and measurement of biomarkers in critical or urgent care patients. STAT Diagnostica is based at Barcelona Science Park and was founded in 2010. Managing Director Jordi Carrera leads the company. It recently raised €2m in Series A financing to advance development of its point-of-care diagnostics platform.

Total raised

$76M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jun 2017